Five things for pharma marketers to know: Monday, August 6, 2018

Share this content:

Regeneron Pharmaceuticals will invest $100 million in bluebird bio, and it plans to work with the cancer-drug manufacturer to create cell-therapy treatments. The companies, which will split the costs of R&D, have identified six initial targets. (Reuters)

Boehringer Ingelheim has started a partnership with U.K.-based academic and research institutions to create a gene therapy for cystic fibrosis.The coalition will work off nearly two decades of research by the U.K. Cystic Fibrosis Gene Therapy Coalition. The category is dominated by Vertex. (Endpoints)

The FDA has rejected Pain Therapeutics' application to sell Remoxy. The long-acting formulation of oxycodone has already been rejected three times by the agency. Shares of the company were down more than 20% in premarket trading. (MarketWatch)

Ovid Therapeutics has reported top-line data that shows gaboxadol, its drug for rare cases of Angelman syndrome, was effective at treating symptoms in a Phase II trial. Investors still have questions about the drug's effectiveness, and the company's stock fell on the news. (Endpoints)

Samumed, a private biotech company working on a range of regenerative treatments for conditions including hair loss, has raised $438 billion. The company has seven clinical trials, two of which are ready to enter late-stage trials. (Business Insider)
Share this content:
Scroll down to see the next article